AUTOLUS THERAPEUTICS PLC - AMERICAN DEPOSITARY SHA

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

14 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in Blood Cancer Journal

11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

29 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in Nature Communications 

22 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Announces Pricing of Underwritten Offering

08 Feb 2024 07:00:46 By Nasdaq GlobeNewswire

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  

08 Feb 2024 05:45:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces publication in ACS Chemical Biology

23 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

10 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Announces Changes to its Board of Directors

22 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

09 Dec 2023 20:30:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)

27 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023

15 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics announces participation in upcoming conferences

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations

02 Nov 2023 09:00:00 By Nasdaq GlobeNewswire

Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

02 Nov 2023 07:11:50 By Nasdaq GlobeNewswire

Autolus Therapeutics to host virtual event to discuss the company’s obe-cel program in systemic lupus erythematosus

17 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 Oct 2023 08:07:12 By Nasdaq GlobeNewswire

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

11 Oct 2023 07:00:00 By Nasdaq GlobeNewswire